Skip to main content
Search
Main content
Will McEwan

Prof Will McEwan

((he/him))

Group Leader

Deciphering the mechanisms of tau accumulation and exploring new methods for treatment of tauopathies

Techniques

Advanced microscopy & imaging, Biophysical techniques, CRISPR, Drug screening, Flow cytometry, Mass spec-based proteomics, Stem cells / iPSCs, Viral-mediated expression

Biography

Prof Will McEwan joined the UK DRI in 2020 with a Wellcome Trust Fellowship following his postdoctoral training at the MRC Laboratory of Molecular Biology in Cambridge. Will trained as a viral immunologist and during his postdoc co-discovered and characterised the novel antibody receptor TRIM21. His team at the UK DRI at Cambridge have demonstrated that TRIM21 can be effective at clearing aggregates in the context of neurodegenerative disease. His group focuses on tau and other intracellular protein aggregates. 

 

News

Key publications

Alzheimer's & dementia : the journal of the Alzheimer's Association
Published
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference
Authors
Bess Frost, James B Rowe, Rufus O Akinyemi, Jose F Abisambra, Nicholas J Ashton, Matthias Brendel, Luc Buée, David Butler, Maria C Carrillo, Peter Chung, Claire D Clelland, Sarah L DeVos, Kristophe Diaz, Rebecca M Edelmayer, Fanny M Elahi, Ratnavalli Ellajosyula, Colin Ewen, Igor Camargo Fontana, Marie-Christine Galas, Oskar Hansson, Günter Höglinger, Kanta Horie, Agustín Ibanez, Linde Jacobs, Mahmoud B Maina, Maura Malpetti, Eric McDade, Will McEwan, Laia Montoliu-Gaya, Catherine J Mummery, Miranda E Orr, Jonathan D Rohrer, Amy Rommel, Carlos Sastre, Tara L Spires-Jones, Boon Lead Tee, Tim J Viney, Jamie M Walker, Susanne Wegmann, Kristin Wildsmith, Ravi Yadav, Simin Mahinrad, Claire Sexton
Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

McEwan Lab

Explore the work of the McEwan Lab, focused on understanding the mechanisms of tau accumulation and exploring new methods for treatment of tauopathies.

GFAP MAP 2 iba1